(Reuters) – Drugmaker Viatris Inc is considering a potential sale of its consumer health assets in Europe in a deal that could be valued at over 3 billion euros ($2.9 billion), Bloomberg News reported on Tuesday, citing people familiar with the matter.
Viatris is working with Jefferies Financial Group Inc as it seeks to identify potential suitors, which could include private equity groups or others seeking to grow in the region, the report said. (https://bloom.bg/3VjsxSc)
Drugmakers including Johnson & Johnson have in the recent past announced plans to separate their consumer health businesses as they seek to focus on their mainstay pharmaceuticals operations.
Viatris, which was formed by the merger of generic drugmaker Mylan and Pfizer Inc’s Upjohn unit, did not immediately respond to a Reuters request for comment.
(Reporting by Raghav Mahobe; Editing by Shailesh Kuber)
